Topic:

Facilities

Latest Headlines

Latest Headlines

Pfizer buys a portion of a vaccine plant from Baxter, J&J sells a vax facility to PaxVax

Pfizer is picking up a "portion" of a Baxter International vaccine manufacturing facility in Orth, Austria, as part of a $635 million deal to buy that company's marketed vaccine portfolio.

Hospira's Rocky Mount plant meets FDA goals, but one in India does not

Hospira's long troubled Rocky Mount, NC, manufacturing plant is troubled no more. CEO F. Michael Ball says a much anticipated reinspection of the plant by the FDA resulted in no observations. But now the FDA's focus has shifted to a new plant in India where manufacturing issues have caught its attention.

Spectacular warehouse burglary left extensive collateral damage for Eli Lilly

The daring burglary of an Eli Lilly warehouse in 2010 was a record-setter by any number of measures. The parsing of the losses in insurance documents serves as a primer for the collateral damage that accrues from a large theft.

Manufacturing takes it on the chin in Amgen cuts

Amgen is cutting up to 2,900 jobs, and the ax-wielding will fall heavily on manufacturing and R&D sites in Colorado and Washington, whose futures were already dim.

Merck KGaA to cut carbon dioxide emissions at Darmstadt site

Germany's Merck KGaA is expanding its headquarters and manufacturing operations in Darmstadt, Germany. On Monday, Merck said it is investing about €27 million (about $36.3 million) to build two power plants that it says will provide more power more efficiently, while reducing carbon dioxide emissions in the area.

Hikma buys closed Boehringer plant and strips out equipment

Jordan's Hikma has decided to pull the trigger on a deal to take ownership of the Boehringer Ingelheim plant in Bedford, OH, one of the largest sterile manufacturing sites in the world but one that sits idle after quality issues made it too expensive to operate.

J&J done with Boehringer plant after building a supply of Doxil

When Boehringer Ingelheim closed its troubled sterile manufacturing site in Ohio, which had been the sole supplier of Johnson & Johnson's ovarian cancer drug Doxil, J&J's Janssen unit worked out a deal to take over manufacturing of the bulk drug product for 6 months. Now, with at least a 9-month supply of Doxil in hand, that arrangement is over.

Out with the new and in with the old after GSK trips up at vaccine plant

Problems with a new manufacturing process at the GlaxoSmithKline influenza vaccine plant in Canada caused some of the issues raised by regulators there, and so the U.K. drugmaker is reverting to its earlier process to get product to the market for the upcoming flu season.

German Merck to start work on new China plant

Merck KGaA will start construction next month on a plant to make diabetes drugs in China, a market it says is key to its future. The market is so important that the executive board of the German drugmaker held an event there to reiterate that point to Chinese officials.

Lilly to cut 100 production jobs in Indianapolis, but workers get shot at others

Eli Lilly says about 100 jobs will be lost in its dry products operations as it rejiggers tablet and capsule production over the next several years, but that employees will have the chance to move to other positions, like in its growing insulin operations.